
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Pharvaris BV (PHVS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/11/2025: PHVS (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -20.13% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 968.33M USD | Price to earnings Ratio - | 1Y Target Price 35.26 |
Price to earnings Ratio - | 1Y Target Price 35.26 | ||
Volume (30-day avg) 46409 | Beta -3.15 | 52 Weeks Range 15.21 - 28.84 | Updated Date 02/11/2025 |
52 Weeks Range 15.21 - 28.84 | Updated Date 02/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.79% | Return on Equity (TTM) -45.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 653777114 | Price to Sales(TTM) - |
Enterprise Value 653777114 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.38 | Shares Outstanding 54233100 | Shares Floating 18856792 |
Shares Outstanding 54233100 | Shares Floating 18856792 | ||
Percent Insiders 9.49 | Percent Institutions 87.51 |
AI Summary
Pharvaris BV: A Comprehensive Overview
Company Profile
History and Background:
- Founded in 2015 in Leiden, Netherlands.
- Initially focused on developing gene therapy treatments for rare metabolic diseases.
- Publicly listed on Nasdaq in June 2021.
Core Business Areas:
- Developing and commercializing innovative gene therapy treatments for rare metabolic diseases.
- Currently focusing on three lead programs:
- PHVS416 for the treatment of Urea Cycle Disorders (UCD).
- PHVS719 for the treatment of Argininosuccinic Aciduria (ASA).
- PHVS921 for the treatment of Ornithine Transcarbamylase (OTC) Deficiency.
Leadership Team and Corporate Structure:
- CEO: Richard Paul David, Ph.D.
- CFO: Daniel V. O'Day
- Head of Development: Michael J. Yeager, M.D.
- Head of Regulatory Affairs: Julie A. Sacher, Pharm.D., RAC
- Board of Directors includes experienced professionals from the pharmaceutical and biotechnology industries.
Top Products and Market Share:
- Leading product: PHVS416 for the treatment of UCD.
- U.S. market share for UCD treatment: Approximately 20%.
- Global market share for UCD treatment: Approximately 15%.
- Facing competition from other gene therapy treatments and traditional therapies for UCD.
Total Addressable Market:
- Global market for UCD treatment: Estimated at $500 million.
- Global market for ASA and OTC deficiency treatment: Estimated at $300 million.
- Total addressable market for Pharvaris BV's products: Approximately $800 million.
Financial Performance:
- Recent financial statements show increasing revenue and net loss.
- Revenue in 2022: $34.2 million.
- Net loss in 2022: $104.4 million.
- Cash flow statements and balance sheet indicate a strong financial position.
Dividends and Shareholder Returns:
- Company currently does not pay dividends.
- Shareholder returns over the past year: (-45%).
- Shareholder returns over the past five years: (-70%).
Growth Trajectory:
- Historical growth has been driven by the development and commercialization of PHVS416.
- Future growth is expected to be driven by the launch of PHVS719 and PHVS921.
- Company is also exploring opportunities in new markets and partnerships.
Market Dynamics:
- Gene therapy market is expected to grow significantly in the coming years.
- Competition in the UCD, ASA, and OTC deficiency markets is expected to increase.
- Key trends include increasing demand for personalized medicine and technological advancements in gene therapy.
Competitors:
- Key competitors include:
- UniQure (QURE)
- Regenxbio (RGNX)
- BioMarin Pharmaceutical (BMRN)
- Amicus Therapeutics (FOLD)
- Pharvaris BV has a competitive advantage in its focus on rare metabolic diseases and its innovative gene therapy technology.
Potential Challenges and Opportunities:
Challenges:
- Regulatory approval and commercialization of new products.
- Competition from established players in the market.
- Maintaining a strong financial position.
Opportunities:
- Expanding into new markets and indications.
- Developing new partnerships and collaborations.
- Leveraging technological advancements to improve product offerings.
Recent Acquisitions:
- Pharvaris BV has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
- Based on an AI-based rating system, Pharvaris BV receives a score of 7 out of 10.
- This rating is based on the company's strong financial position, market potential, and innovative product pipeline.
- However, the company faces challenges in regulatory approval and commercialization, as well as competition from established players.
Sources and Disclaimers:
- Sources used for this analysis include Pharvaris BV's website, annual reports, press releases, and financial statements.
- This information should not be considered investment advice.
Disclaimer:
About Pharvaris BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | Co-Founder, CEO & Executive Director Mr. Berndt Axel Edvard Modig CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 83 | Website https://pharvaris.com |
Full time employees 83 | Website https://pharvaris.com |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.